Compare INTT & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTT | MGNX |
|---|---|---|
| Founded | 1981 | 2000 |
| Country | United States | United States |
| Employees | 407 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.0M | 220.6M |
| IPO Year | 1997 | 2013 |
| Metric | INTT | MGNX |
|---|---|---|
| Price | $18.37 | $3.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $13.50 | $5.00 |
| AVG Volume (30 Days) | 294.8K | ★ 720.9K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $66,801,000.00 | ★ $149,500,000.00 |
| Revenue This Year | $15.82 | N/A |
| Revenue Next Year | $9.10 | $3.19 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 66.06 | N/A |
| 52 Week Low | $5.64 | $1.19 |
| 52 Week High | $20.00 | $3.88 |
| Indicator | INTT | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 64.14 | 50.88 |
| Support Level | $7.37 | $1.45 |
| Resistance Level | N/A | $3.26 |
| Average True Range (ATR) | 1.60 | 0.20 |
| MACD | 0.11 | -0.06 |
| Stochastic Oscillator | 73.15 | 31.29 |
inTest Corp is a supplier of test and process technology solutions for use in manufacturing and testing across a wide range of markets, including Semi, Auto/EV, Defense/Aerospace, Industrial, Life Sciences, Safety/Security, and Other. The Company has three operating segments, which are also its reportable segments and reporting units: Electronic Test, which generates the majority of its revenue and includes semiconductor test equipment, flying probe, and in-circuit testers; Environmental Technologies, which includes thermal test, process, and storage products; and Process Technologies, which includes induction heating and video imaging products. The Company generates the maximum revenue from the U.S.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.